Lixisenatide continues to impress in Phase III
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis/Zealand Pharma's once-daily GLP-1 receptor agonist lixisenatide achieved its primary endpoint in a third Phase III trial.